Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Eli Lilly and Company

Drug Profile

Research programme: cancer therapeutics - Eli Lilly and Company

Alternative Names: DNA checkpoint project - ICOS; Research programme: cell cycle checkpoint/DNA repair inhibitors - ICOS

Latest Information Update: 02 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma; ICOS Corporation
  • Developer Array BioPharma; Eli Lilly and Company
  • Class
  • Mechanism of Action Checkpoint kinase inhibitors; DNA repair inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 30 Jul 2019 Array BioPharma has been acquired by Pfizer
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
  • 30 Jun 2016 Eli Lilly and Company enters into an agreement with Regen BioPharma to initiate an Open Innovation Drug Discovery Program for the treatment of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top